Beyond Ethnicity: Why Mechanism-Driven Endpoints Translate Across Populations

Global clinical development is undergoing a critical shift, as long-held misconceptions are increasingly shaping decisions more than scientific rigor. One of the most persistent is the belief that clinical data generated in non-Caucasian populations inherently carries limited relevance for Caucasian markets due to genetic or ethnic variability. In practice, this assumption continues to influence protocol design, encourage conservative population selection, justify precautionary bridging studies, and extend development timelines, despite regulatory guidance that places greater emphasis on clinical relevance than on geography alone.

This perspective is shaped by long-standing industry practice. For many multinational sponsors (pharma, nutra, device, etc), proximity has traditionally been associated with predictability, preferring local recruitment and local CROs for claim substantiation in Western markets. As a result, population selection has often reflected sponsor comfort rather than biological necessity. As a global CRO, we routinely receive enquiries from Caucasian sponsors (mostly food supplement companies) who insist on recruitment restricted to Caucasian populations, even when this significantly increases study cost and operational complexity without materially strengthening scientific interpretability.

The distinction between science and popular perception is grounded in core regulatory guidance. The ICH E5 framework does not treat ethnicity as a categorical barrier to extrapolation. Instead, it treats ethnic and regional differences as variables whose clinical relevance must be evaluated, not presumed. The regulatory question has never been whether populations differ genetically, but whether those differences meaningfully alter pharmacology, biological response, or end point interpretation.¹ Even Japan no longer has a strong rationale to insist on bridging studies for all approvals. Meanwhile, ethnic diversity in the West is already increasing and is expected to continue rapidly. In 2023-2024, Germany reported 19.5% foreign-born residents. And 41% of those under age 15 years were foreign-born. Soon a trial done exclusively in Europe will still remain costlier, but may represent global ethnicity. Hence there may be an even stronger case to outsource to cheaper non-Caucasian geographies.

Yet in practice, ethnicity is often used as a proxy for uncertainty that originates elsewhere. When end points are weakly aligned with the mechanism, when outcomes rely heavily on subjective perception, or when biological rationale is insufficiently articulated, population differences become a convenient explanation for data that fails to convince. Geography is blamed for what are, in reality, design and measurement challenges.

No clinical outcome exists without genetic influence. Genetic variability is present across continents, within regions, and even within relatively homogeneous Caucasian cohorts. Regulatory acceptance has never required genetic uniformity. What regulators assess is whether variability changes the biological mechanism being measured or alters the meaning of the observed effect. When it does not, extrapolation is routine.

Certain outcomes are grounded in conserved human physiology. Gut barrier integrity, for example, reflects tightly regulated structural and functional biology. While diet and microbiome composition may vary across populations, epithelial repair, tight-junction regulation, and permeability control are conserved processes. When trials focus on objective markers of barrier function rather than symptom perception, the resulting data reflect biology rather than cultural context.

Systemic inflammation follows a similar pattern. Baseline inflammatory tone may differ due to lifestyle or environmental exposure, but biomarkers such as C-reactive protein and interleukin-6 respond directionally to intervention across populations. This consistency explains their routine use in multinational trials and their acceptance in global regulatory submissions.

Muscle function outcomes such as strength, endurance, and fatigue resistance are likewise anchored in conserved pathways in neuromuscular signalling, mitochondrial adaptation, and muscle fiber recruitment. When assessed as within-subject change rather than absolute performance, these end points remain interpretable despite genetic diversity, supporting their widespread use in sports nutrition and healthy aging research.

Protein digestion and utilization reinforce the same logic. While lactose intolerance demonstrates clear ethnic variation, protein digestion does not. The enzymatic systems responsible for protein breakdown and amino acid absorption are highly conserved. With appropriate dietary control, nitrogen balance and protein utilization data generated in Indian populations can be reliably extrapolated to Western markets.

Osteoarthritis provides an instructive example of how end point choice, rather than the disease itself, determines extrapolability. Most osteoarthritis trials rely on patient-reported outcomes such as the WOMAC score to capture pain, stiffness, and functional limitation. These measures are clinically meaningful but are inherently influenced by cultural, behavioral, and psychosocial factors. Where osteoarthritis studies incorporate objective or biologically anchored measures such as inflammatory markers or imaging-based structural assessments, such as cartilage thickness or synovial inflammation/synovitis as supportive or secondary end points, these outcomes tend to reflect conserved pathophysiology and are less sensitive to population context. In osteoarthritis, what varies across populations is not the disease itself, but the end points selected to represent it.

A similar pattern is observed in irritable bowel syndrome. Core mechanisms involving gut motility, visceral sensitivity, and gut–brain axis signalling are conserved, yet clinical trials predominantly rely on symptom scores such as pain, bloating, and stool urgency. These experience-based end points are strongly shaped by dietary habits, symptom perception, and reporting behavior, introducing population sensitivity that does not necessarily reflect differences in underlying biology.

Even trials involving metabolic end points, often cited as the most ethnicity-sensitive, can be done globally and used locally. Differences in insulin resistance patterns across populations are well documented, but they do not invalidate outcomes such as HbA1c, triglycerides, or insulin sensitivity.

By contrast, certain end points are genuinely population-sensitive. Subjective symptom scales, appetite and satiety perception, neurobehavioral outcomes, and pharmacogenetically sensitive drug responses can vary meaningfully across ethnic groups. In such cases, additional data or bridging studies may be justified, not because the population is Asian or African, but because the end point itself lacks biological stability.

Epigenetics and lifestyle further complicate simplistic ethnic assumptions. Diet, physical activity, sleep, stress, and environmental exposure continuously modulate gene expression across all populations. In many nutritional, metabolic, and inflammatory conditions, these modifiable influences exert a stronger effect on outcomes than inherited genetic variation. When studies capture mechanism-level biological change, epigenetic responsiveness strengthens rather than weakens the case for extrapolation to global trials.

This leads to a necessary conclusion. When clinical data generated in non-Caucasian populations fail to support global claims, ethnicity is rarely the primary cause. More often, the limitation lies in end point selection, trial design, or an overreliance on perception-based outcomes.

Poorly chosen end points fail everywhere. Well-anchored biology travels across borders.

The more relevant question is no longer whether Indian or Chinese data can support Caucasian markets, but whether a study is measuring a conserved biological mechanism or a culturally variable experience. When the former is true, trials conducted outside traditional Western populations offer clear advantages of speed, cost efficiency, and high-quality evidence without compromising regulatory credibility.

Ethnicity remains relevant where outcomes are shaped by perception rather than biology. When end points are mechanistically grounded, ethnic considerations become secondary. This reality, rather than proximity, explains why well-designed clinical data translates across populations, whatever be the intervention—drug, medical device or food supplement.

Reference

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1). Published February 5, 1998. Accessed March 6, 2026. https://database.ich.org/sites/default/files/E5_R1__Guideline.pdf